We utilise EpiSwitch™, a proprietary biomarker discovery platform licenced from our AIM listed shareholder Oxford Biodynamics Plc. Holos biomarkers are binary, stable and have both predictive and prognostic value. EpiSwitch™ is based on the latest advances in gene expression, non-coding RNA and epigenetics.

Chromosome Conformation Signatures (CCSs)

EpiSwitch™ is used to monitor a class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (CCSs).

CCSs: Functional Relevance 

  • Provides insight into relevant changes in the regulation of the genome 

  • Shows consistency with genetic and gene expression patient profiles

  • Offers powerful and stable analytical biomarker discovery

CSS_benefits_table.jpg
 

Source: Alicia Carmichael - University of Michigan
Biosocial Methods Collaborative

Source: XXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX